Edwards Lifesciences (EW) Revenue — Quarter Ended Mar 31, 2023
Revenue for the quarter moved sharply higher, reversing the steep decline seen in the preceding quarter. Compared with the same period one year earlier, however, revenue was lower.
Key takeaway
Quarter ended Mar 31, 2023 · FY2023 Q1
Revenue for the quarter moved sharply higher, reversing the steep decline seen in the preceding quarter. Compared with the same period one year earlier, however, revenue was lower.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$1.2B
Revenue reported for this quarter.
Quarter-over-quarter
+184.1%
Change from the immediately preceding quarter.
Year-over-year
-8.9%
Change from the comparable year-ago quarter.
Trailing four quarters
$4.3B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jun 30, 2022 | $1.4B | -0.2% |
| Sep 30, 2022 | $1.3B | +0.7% |
| Dec 31, 2022 | $429.9M | -67.7% |
| Mar 31, 2023 | $1.2B | -8.9% |
Revenue performance
The reported revenue direction is positive, as the quarterly total increased significantly relative to the immediately prior quarter.
Quarterly comparison
On a sequential basis, revenue improved markedly from the preceding quarter. Compared with the same quarter one year earlier, revenue declined.
What to watch
The filing context offers no explanation for the revenue swings, so the sustainability of the sequential recovery is uncertain.